Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H30N8O |
Molecular Weight | 434.5373 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N4CCNCC4)N=C2N1C5CCCC5
InChI
InChIKey=RHXHGRAEPCAFML-UHFFFAOYSA-N
InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)
Molecular Formula | C23H30N8O |
Molecular Weight | 434.5373 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 07:57:54 UTC 2023
by
admin
on
Sat Dec 16 07:57:54 UTC 2023
|
Record UNII |
TK8ERE8P56
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175605
Created by
admin on Sat Dec 16 07:57:54 UTC 2023 , Edited by admin on Sat Dec 16 07:57:54 UTC 2023
|
||
|
WHO-ATC |
L01XE42
Created by
admin on Sat Dec 16 07:57:54 UTC 2023 , Edited by admin on Sat Dec 16 07:57:54 UTC 2023
|
||
|
FDA ORPHAN DRUG |
912722
Created by
admin on Sat Dec 16 07:57:54 UTC 2023 , Edited by admin on Sat Dec 16 07:57:54 UTC 2023
|
||
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 16 07:57:54 UTC 2023 , Edited by admin on Sat Dec 16 07:57:54 UTC 2023
|
||
|
NCI_THESAURUS |
C2185
Created by
admin on Sat Dec 16 07:57:54 UTC 2023 , Edited by admin on Sat Dec 16 07:57:54 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C95701
Created by
admin on Sat Dec 16 07:57:54 UTC 2023 , Edited by admin on Sat Dec 16 07:57:54 UTC 2023
|
PRIMARY | |||
|
m12002
Created by
admin on Sat Dec 16 07:57:54 UTC 2023 , Edited by admin on Sat Dec 16 07:57:54 UTC 2023
|
PRIMARY | |||
|
DE-29
Created by
admin on Sat Dec 16 07:57:54 UTC 2023 , Edited by admin on Sat Dec 16 07:57:54 UTC 2023
|
PRIMARY | |||
|
TK8ERE8P56
Created by
admin on Sat Dec 16 07:57:54 UTC 2023 , Edited by admin on Sat Dec 16 07:57:54 UTC 2023
|
PRIMARY | |||
|
DTXSID201021027
Created by
admin on Sat Dec 16 07:57:54 UTC 2023 , Edited by admin on Sat Dec 16 07:57:54 UTC 2023
|
PRIMARY | |||
|
9968
Created by
admin on Sat Dec 16 07:57:54 UTC 2023 , Edited by admin on Sat Dec 16 07:57:54 UTC 2023
|
PRIMARY | |||
|
SUB180246
Created by
admin on Sat Dec 16 07:57:54 UTC 2023 , Edited by admin on Sat Dec 16 07:57:54 UTC 2023
|
PRIMARY | |||
|
CHEMBL3545110
Created by
admin on Sat Dec 16 07:57:54 UTC 2023 , Edited by admin on Sat Dec 16 07:57:54 UTC 2023
|
PRIMARY | |||
|
Ribociclib
Created by
admin on Sat Dec 16 07:57:54 UTC 2023 , Edited by admin on Sat Dec 16 07:57:54 UTC 2023
|
PRIMARY | |||
|
DB11730
Created by
admin on Sat Dec 16 07:57:54 UTC 2023 , Edited by admin on Sat Dec 16 07:57:54 UTC 2023
|
PRIMARY | |||
|
44631912
Created by
admin on Sat Dec 16 07:57:54 UTC 2023 , Edited by admin on Sat Dec 16 07:57:54 UTC 2023
|
PRIMARY | |||
|
Ribociclib
Created by
admin on Sat Dec 16 07:57:54 UTC 2023 , Edited by admin on Sat Dec 16 07:57:54 UTC 2023
|
PRIMARY | |||
|
5218
Created by
admin on Sat Dec 16 07:57:54 UTC 2023 , Edited by admin on Sat Dec 16 07:57:54 UTC 2023
|
PRIMARY | |||
|
TK8ERE8P56
Created by
admin on Sat Dec 16 07:57:54 UTC 2023 , Edited by admin on Sat Dec 16 07:57:54 UTC 2023
|
PRIMARY | |||
|
100000166185
Created by
admin on Sat Dec 16 07:57:54 UTC 2023 , Edited by admin on Sat Dec 16 07:57:54 UTC 2023
|
PRIMARY | |||
|
1211441-98-3
Created by
admin on Sat Dec 16 07:57:54 UTC 2023 , Edited by admin on Sat Dec 16 07:57:54 UTC 2023
|
PRIMARY | |||
|
1873916
Created by
admin on Sat Dec 16 07:57:54 UTC 2023 , Edited by admin on Sat Dec 16 07:57:54 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
EXCRETED UNCHANGED |
FECAL
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
Coadministration of a strong CYP3A4 inducer (rifampin) decreased the plasma AUC of ribociclib by 89%. The concomitant use of strong CYP3A4 inducers with ribociclib should be avoided.: In a dedicated drug-interaction trial, concomitant ritonavir (a strong CYP3A4 inhibitor) increased a single dose ribociclib’s Cmax by 1.7-fold and the AUC by 3.2-fold.
|
||
|
EXCRETED UNCHANGED |
URINE
|
||
|
TRANSPORTER -> INHIBITOR |
Ki
|
||
|
TRANSPORTER -> INHIBITOR |
Ki
|
||
|
METABOLIC ENZYME -> INHIBITOR |
A time-dependent inhibitor (TDI) of CYP3A4/5 (Ki,u: 4.44 μM; kinact: 0.02 min-1 ). In vivo, ribociclib is a CYP3A perpetrator . Ribociclib dosed at 400 mg QD increased the coadministrated midazolam (a sensitive CYP3A4 substrate) AUC by 3.8-fold. Ribociclib given at the recommended dose of 600 mg QD is predicted to increase the midazolam AUC by 5.2-fold.
TIME-DEPENDENT INHIBITION
Ki
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> INHIBITOR |
Ki
|
||
|
TARGET -> INHIBITOR |
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |